Butanvac (Coronavirus Vaccine) / Oswaldo Cruz Foundation, Butantan Institute 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Butanvac (Coronavirus Vaccine) / Oswaldo Cruz Foundation, Butantan Institute
NCT05354024: Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine

Active, not recruiting
2/3
4400
RoW
NDV-HXP-S 10μg, BNT162b2 30μg
Butantan Institute
Coronavirus Infections, Healthy
10/23
09/24
NCT05940194: NDV-HXP-S Vaccine Clinical Trial (COVIVAC)

Completed
2
374
RoW
COVIVAC vaccine
Institute of Vaccines and Medical Biologicals, Vietnam, National Institute of Hygiene and Epidemiology (NIHE), Vietnam, Center for Disease Control of Thai Binh Province, Vietnam
COVID-19
10/21
03/22
ADAPTCOV, NCT04993209: Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil

Completed
1
320
RoW
NDV-HXP-S 1μg, NDV-HXP-S 3μg, NDV-HXP-S 10μg, Adsorbed inactivated COVID-19 vaccine (CoronaVac)
Butantan Institute
Coronavirus Infections, Healthy
12/21
11/22
NCT05181709: A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.

Active, not recruiting
1
35
US
Sodium Chloride, Placebo, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose, NDV-HXP-S IN high dose, NDV-HXP-S IM high dose
Sean Liu
SARS-CoV-2
05/23
04/24

Download Options